We are in the midst of the era of Sustainable Business, a transformative period where the decisions we make today are shaping the future of our planet.
PHAXIAM Therapeutics (NASDAQ:PHXM – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk. Analyst Recommendations This is a breakdown of current […]
PHAXIAM Therapeutics S.A. (NASDAQ:PHXM – Free Report) shares are going to reverse split before the market opens on Wednesday, September 20th. The 1-10 reverse split was announced on Wednesday, September 20th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, September 20th. PHAXIAM Therapeutics Price Performance Shares of […]
PHAXIAM Therapeutics (NASDAQ:PHXM – Get Free Report) is scheduled to announce its earnings results after the market closes on Thursday, September 21st. PHAXIAM Therapeutics Stock Performance Shares of PHAXIAM Therapeutics stock opened at $0.42 on Friday. The business has a fifty day moving average price of $0.56. The company has a quick ratio of 3.65, […]
HR Research: Employee-Centered Experience Drives Business Agility In Australia
Share to Linkedin
A recent study showed the vast majority of surveyed Australians said their organization had effectively handled new ways of working in response to COVID-19 (80%), and was well prepared to address the changing work environment (78%).
That said, Australian executives may be underestimating upcoming challenges. Less than half (47%) expected COVID-19 to increase flexibility for remote work over the next year. They did expect that maintaining productivity given new ways of working (49%) and establishing a culture that supported more remote employees (44%) would become top challenges for businesses, but at a far lower percentage than many other countries in the survey.